122 related articles for article (PubMed ID: 16399433)
21. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
Galizia G; Lieto E; De Vita F; Orditura M; Castellano P; Troiani T; Imperatore V; Ciardiello F
Oncogene; 2007 May; 26(25):3654-60. PubMed ID: 17530019
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Meyerhardt JA; Heseltine D; Ogino S; Clark JW; Enzinger PC; Ryan DP; Earle CC; Zhu AX; Fuchs CS
Clin Colorectal Cancer; 2006 May; 6(1):59-65. PubMed ID: 16796793
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab in combination therapy: from bench to clinic.
Gerber DE; Choy H
Cancer Metastasis Rev; 2010 Mar; 29(1):171-80. PubMed ID: 20140759
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Köhne CH; Lenz HJ
Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab: in the treatment of metastatic colorectal cancer.
Reynolds NA; Wagstaff AJ
Drugs; 2004; 64(1):109-18; discussion 119-121. PubMed ID: 14723561
[TBL] [Abstract][Full Text] [Related]
26. The role of targeted therapy in the treatment of colorectal cancer.
Goldberg RM; Hurwitz HI; Fuchs CS
Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor inhibitors and colorectal cancer.
Meyerhardt JA; Fuchs CS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):35-8. PubMed ID: 15685832
[TBL] [Abstract][Full Text] [Related]
28. [The role of chemotherapy and targeted antiVEGF- and antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and intensive response].
Nemecek R; Vyzula R
Klin Onkol; 2011; 24(6):465-9. PubMed ID: 22257237
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab in the treatment of colorectal cancer.
Ciardiello F; De Vita F; Orditura M; Comunale D; Galizia G
Future Oncol; 2005 Apr; 1(2):173-81. PubMed ID: 16555987
[TBL] [Abstract][Full Text] [Related]
30. Development and clinical indications of cetuximab.
Labianca R; La Verde N; Garassino MC
Int J Biol Markers; 2007; 22(1 Suppl 4):S40-6. PubMed ID: 17520580
[TBL] [Abstract][Full Text] [Related]
31. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
Halama N; Herrmann C; Jaeger D; Herrmann T
Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab plus irinotecan in refractory colorectal cancer patients.
Gil Delgado M; Spano JP; Khayat D
Expert Rev Anticancer Ther; 2007 Apr; 7(4):407-13. PubMed ID: 17428161
[TBL] [Abstract][Full Text] [Related]
33. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
34. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.
Delbaldo C; Pierga JY; Dieras V; Faivre S; Laurence V; Vedovato JC; Bonnay M; Mueser M; Nolting A; Kovar A; Raymond E
Eur J Cancer; 2005 Aug; 41(12):1739-45. PubMed ID: 16051481
[TBL] [Abstract][Full Text] [Related]
36. Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient.
Tonini G; Vincenzi B; Santini D; Olzi D; Lambiase A; Bonini S
J Natl Cancer Inst; 2005 Apr; 97(8):606-7. PubMed ID: 15840884
[No Abstract] [Full Text] [Related]
37. Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.
Altundag K; Silay YS; Altundag O; Yigitbasi OG; Gundeslioglu O; Gunduz M
Med Hypotheses; 2005; 64(6):1162-5. PubMed ID: 15823708
[TBL] [Abstract][Full Text] [Related]
38. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
Hebbar M; Wacrenier A; Desauw C; Romano O; Cattan S; Triboulet JP; Pruvot FR
Anticancer Drugs; 2006 Aug; 17(7):855-7. PubMed ID: 16926635
[TBL] [Abstract][Full Text] [Related]
39. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab.
Rodríguez J; Viúdez A; Ponz-Sarvisé M; Gil-Aldea I; Chopitea A; García-Foncillas J; Gil-Bazo I
Crit Rev Oncol Hematol; 2010 Jun; 74(3):193-202. PubMed ID: 19700342
[TBL] [Abstract][Full Text] [Related]
40. EGFR-targeted therapies in colorectal cancer.
Overman MJ; Hoff PM
Dis Colon Rectum; 2007 Aug; 50(8):1259-70. PubMed ID: 17566832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
